Relevant bibliographies by topics / Receptory progesteronowe

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Receptory progesteronowe'

Author: Grafiati
Published: 24 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Receptory progesteronowe.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Receptory progesteronowe"

1

Cato, A. C., and H. Ponta. "Different regions of the estrogen receptor are required for synergistic action with the glucocorticoid and progesterone receptors." Molecular and Cellular Biology 9, no. 12 (December 1989): 5324–30. http://dx.doi.org/10.1128/mcb.9.12.5324.

Full text
Abstract:
Estrogen and progesterone or estrogen and glucocorticoid receptors functionally cooperate in gene activation if their cognate binding sites are close to one another. These interactions have been described as synergism of action of the steroid receptors. The mechanism by which synergism is achieved is not clear, although protein-protein interaction of the receptors is one of the favorite models. In transfection experiments with receptor expression vectors and a reporter gene containing estrogen and progesterone-glucocorticoid receptor binding sites, we have examined the effects that different portions of the various receptors have on synergism. N-terminal domains of the chicken progesterone and human glucocorticoid receptors, when deleted, abolished the synergistic action of these receptors with the estrogen receptor. Deletion of the carboxy-terminal amino acids 341 to 595 of the estrogen receptor produced a mutant receptor that could not trans-activate on its own. This mutant receptor did not affect the action of the glucocorticoid receptor but functioned synergistically with the progesterone receptor. We therefore conclude that the synergistic action of the receptors for estrogen and progesterone is mechanistically different from the synergistic action of the receptors for estrogen and glucocorticoid.
APA, Harvard, Vancouver, ISO, and other styles
2

Cato, A. C., and H. Ponta. "Different regions of the estrogen receptor are required for synergistic action with the glucocorticoid and progesterone receptors." Molecular and Cellular Biology 9, no. 12 (December 1989): 5324–30. http://dx.doi.org/10.1128/mcb.9.12.5324-5330.1989.

Full text
Abstract:
Estrogen and progesterone or estrogen and glucocorticoid receptors functionally cooperate in gene activation if their cognate binding sites are close to one another. These interactions have been described as synergism of action of the steroid receptors. The mechanism by which synergism is achieved is not clear, although protein-protein interaction of the receptors is one of the favorite models. In transfection experiments with receptor expression vectors and a reporter gene containing estrogen and progesterone-glucocorticoid receptor binding sites, we have examined the effects that different portions of the various receptors have on synergism. N-terminal domains of the chicken progesterone and human glucocorticoid receptors, when deleted, abolished the synergistic action of these receptors with the estrogen receptor. Deletion of the carboxy-terminal amino acids 341 to 595 of the estrogen receptor produced a mutant receptor that could not trans-activate on its own. This mutant receptor did not affect the action of the glucocorticoid receptor but functioned synergistically with the progesterone receptor. We therefore conclude that the synergistic action of the receptors for estrogen and progesterone is mechanistically different from the synergistic action of the receptors for estrogen and glucocorticoid.
APA, Harvard, Vancouver, ISO, and other styles
3

Johannessen, Molly, Dominique Fontanilla, Timur Mavlyutov, Arnold E. Ruoho, and Meyer B. Jackson. "Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels." American Journal of Physiology-Cell Physiology 300, no. 2 (February 2011): C328—C337. http://dx.doi.org/10.1152/ajpcell.00383.2010.

Full text
Abstract:
σ-Receptors are integral membrane proteins that have been implicated in a number of biological functions, many of which involve the modulation of ion channels. A wide range of synthetic ligands activate σ-receptors, but endogenous σ-receptor ligands have proven elusive. One endogenous ligand, dimethyltryptamine (DMT), has been shown to act as a σ-receptor agonist. Progesterone and other steroids bind σ-receptors, but the functional consequences of these interactions are unclear. Here we investigated progesterone binding to σ1- and σ2-receptors and evaluated its effect on σ-receptor-mediated modulation of voltage-gated Na+ channels. Progesterone binds both σ-receptor subtypes in liver membranes with comparable affinities and blocks photolabeling of both subtypes in human embryonic kidney 293 cells that stably express the human cardiac Na+ channel Nav1.5. Patch-clamp recording in this cell line tested Na+ current modulation by the σ-receptor ligands ditolylguanidine, PB28, (+)SKF10047, and DMT. Progesterone inhibited the action of these ligands to varying degrees, and some of these actions were reduced by σ1-receptor knockdown with small interfering RNA. Progesterone inhibition of channel modulation by drugs was consistent with stronger antagonism of σ2-receptors. By contrast, progesterone inhibition of channel modulation by DMT was consistent with stronger antagonism of σ1-receptors. Progesterone binding to σ-receptors blocks σ-receptor-mediated modulation of a voltage-gated ion channel, and this novel membrane action of progesterone may be relevant to changes in brain and cardiovascular function during endocrine transitions.
APA, Harvard, Vancouver, ISO, and other styles
4

Grunberg, Steven M., Anna Marie Daniels, Helmut Muensch, John R. Daniels, Leslie Bernstein, Virginia Kortes, and Martin H. Weiss. "Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay." Journal of Neurosurgery 66, no. 3 (March 1987): 405–8. http://dx.doi.org/10.3171/jns.1987.66.3.0405.

Full text
Abstract:
✓ Several investigators have detected progesterone receptors in a high percentage of meningioma specimens and have noted progesterone receptors to be more common than estrogen receptors in these specimens. However, a functional significance of such hormone receptor positivity in control of meningioma growth has not been described. This paper describes a paired test of the estrogen and progesterone receptor assay as the biochemical assay and of the human tumor stem-cell clonogenic assay (HTSCCA) as the functional assay in 17 meningioma specimens. Only one (6%) of the 17 specimens was estrogen receptor-positive, while 11 (69%) of 16 specimens were progesterone receptor-positive. The HTSCCA revealed that only two (15%) of 13 specimens were sensitive to estradiol while five (31%) of 16 specimens were sensitive to progesterone. Comparison of progesterone results for the 15 specimens on which both hormone receptor assay and HTSCCA were performed revealed correlation in a majority of cases; four specimens were positive for both assays and five specimens were negative for both assays. No specimen that was negative for progesterone receptors was sensitive to progesterone by HTSCCA. These results suggest that the hormone receptor and sensitivity pattern of meningiomas may differ from that of breast cancer, and that progesterone addition or ablation may be a reasonable therapeutic approach for meningiomas.
APA, Harvard, Vancouver, ISO, and other styles
5

Mangal, Suruchi, Manisha Sharma, Mridu Manjari, Rahul Mannan, and Sunit Tandon. "Expression Of Androgen Receptor, Estrogen Receptor And Progesterone Receptor In Endometrial Carcinoma (Immunohistochemical Study)." Annals of Pathology and Laboratory Medicine 7, no. 5 (May 28, 2020): A248–252. http://dx.doi.org/10.21276/apalm.2726.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Berg, Nicholas J., Douglas S. Colvard, H. Bryan Neel, Louis H. Weiland, and Thomas C. Spelsberg. "Progesterone Receptors in Carcinomas of the Upper Aerodigestive Tract." Otolaryngology–Head and Neck Surgery 101, no. 5 (November 1989): 527–36. http://dx.doi.org/10.1177/019459988910100503.

Full text
Abstract:
This study had three major goals: (1) to vigorously verify the presence of progesterone receptors in squamous cell carcinoma of the upper aerodigestive tract (HN-SCC). Antiprogesterone receptor monoclonal antibodies revealed a distinct band at approximately 120 kilodaltons in samples taken from two of four patients with HN-SCC. These results illustrate that progesterone receptor in HN-SCC has the same molecular weight as progesterone receptor in normal human uterus and human breast cancer. Steroid specificity and saturability results support the evidence that it is true progesterone receptors that are measured and not other receptors or sex steroid-binding globulins; (2) to confirm the biochemical function of progesterone receptors in HN-SCC by assessing the binding of progesterone receptor to acceptor sites on chromosomes in the nucleus; and (3) to establish the clinical significance of progesterone receptor measurement. Patients with positive assays were more likely to be free of disease a mean of 6 months after resection. We used logistic regression to account for site of primary disease, grade of tumor, and stage of disease. This logistic regression was significant with a p = 0.014. Patients with a binding index greater than 2 (19 of 73 patients) were 4.34 times more likely to be free of disease than patients with negative assays.
APA, Harvard, Vancouver, ISO, and other styles
7

Wathes, D. C., G. E. Mann, J. H. Payne, P. R. Riley, K. R. Stevenson, and G. E. Lamming. "Regulation of oxytocin, oestradiol and progesterone receptor concentrations in different uterine regions by oestradiol, progesterone and oxytocin in ovariectomized ewes." Journal of Endocrinology 151, no. 3 (December 1996): 375–93. http://dx.doi.org/10.1677/joe.0.1510375.

Full text
Abstract:
Abstract The regulation of oxytocin, oestradiol and progesterone receptors in different uterine cell types was studied in ovariectomized ewes. Animals were pretreated with a progestogen sponge for 10 days followed by 2 days of high-dose oestradiol to simulate oestrus. They then received either low-dose oestradiol (Group E), low-dose oestradiol plus progesterone (Group P) or low-dose oestradiol, progesterone and oxytocin (via osmotic minipump; Group OT). Animals (three to six per time-point) were killed following ovariectomy (Group OVX), at oestrus (Group O) or following 8, 10, 12 or 14 days of E, P or OT treatment. In a final group, oxytocin was withdrawn on day 12 and ewes were killed on day 14 (Group OTW). Oxytocin receptor concentrations and localization in the endometrium and myometrium were measured by radioreceptor assay, in situ hybridization and autoradiography with the iodinated oxytocin receptor antagonist d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH29]-vasotocin. Oestradiol and progesterone receptors were localized by immunocytochemistry. Oxytocin receptors were present in the luminal epithelium and superficial glands of ovariectomized ewes. In Group O, endometrial oxytocin receptor concentrations were high (1346 ± 379 fmol [3H]oxytocin bound mg protein−1) and receptors were also located in the deep glands and caruncular stroma in a pattern resembling that found at natural oestrus. Continuing low-dose oestradiol was unable to sustain high endometrial oxytocin receptor concentrations with values decreasing significantly to 140 ± 20 fmol mg protein−1 (P<0·01), localized to the luminal epithelium and caruncular stroma but not the glands. Progesterone treatment initially abolished all oxytocin receptors with none present on days 8 or 10. They reappeared in the luminal epithelium only between days 12 and 14 to give an overall concentration of 306 ± 50 fmol mg protein−1. Oxytocin treatment caused a small increase in oxytocin receptor concentration in the luminal epithelium on days 8 and 10 (20 ± 4 in Group P and 107 ± 35 fmol mg protein−1 in Group OT, P<0·01) but the rise on day 14 was not affected (267 ± 82 in Group OT and 411 ± 120 fmol mg protein−1 in Group OTW). In contrast, oestradiol treatment was able to sustain myometrial oxytocin receptors (635 ± 277 fmol mg protein−1 in Group O and 255 ± 36 in Group E) and there was no increase over time in Groups P, OT and OTW with values of 61 ± 18, 88 ± 53 and 114 ± 76 fmol mg protein−1 respectively (combined values for days 8–14). Oestradiol receptor concentrations were high in all uterine regions in Group O. This pattern and concentration was maintained in Group E. In all progesterone-treated ewes, oestradiol receptor concentrations were lower in all regions at all time-points. The only time-related change occurred in the luminal epithelium in which oestradiol receptors were undetectable on day 8 but developed by day 10 of progesterone treatment. Progesterone receptors were present at moderate concentrations in the deep glands, caruncular stroma, deep stroma and myometrium in Group O. Oestradiol increased progesterone receptors in the luminal epithelium, superficial glands, deep stroma and myometrium. Progesterone caused the loss of its own receptor from the luminal epithelium and superficial glands and decreased its receptor concentration in the deep stroma and myometrium at all time-points. There was a time-related loss of progesterone receptors from the deep glands of progesterone-treated ewes between days 8 and 14. These results show differences in the regulation of receptors between uterine regions. In particular, loss of the negative inhibition by progesterone on the oxytocin receptor by day 14 occurred only in the luminal epithelium, but is unlikely to be a direct effect of progesterone as no progesterone receptors were present on luminal epithelial cells between days 8 and 14. The presence of oxytocin receptors in the luminal epithelium of ovariectomized ewes suggests that oestradiol is not essential for oxytocin receptor synthesis at this site. Oestradiol was able to sustain its own receptor at all sites, but high circulating progesterone was always inhibitory to oestradiol receptors. In general, oestradiol stimulated progesterone receptors in epithelial cells whereas progesterone abolished its own receptor from epithelial cells over a period of time, but had a lesser effect on stromal cells. The concentration of all three receptors is therefore differentially regulated between different uterine cell types, suggesting the importance of paracrine effects which remain to be elucidated. Journal of Endocrinology (1996) 151, 375–393
APA, Harvard, Vancouver, ISO, and other styles
8

Bracali, G., A. M. Caracino, F. Rossodivita, C. Bianchi, M. G. Loli, and M. Bracali. "Estrogen and Progesterone Receptors in Human Colorectal Tumour Cells (Study of 70 Cases)." International Journal of Biological Markers 3, no. 1 (January 1988): 41–48. http://dx.doi.org/10.1177/172460088800300108.

Full text
Abstract:
Estrogen and progesterone receptors were studied in 70 cases of human colorectal cancer by a cytochemical technique. 28.5% of the cases were estrogen-receptor positive and 42.8% progesterone-receptor positive. There was no difference between the sexes for estrogen receptors but the women had more tumours with progesterone receptors than men. The presence of receptors is unrelated to the differentiation of the tumour. More colon tumours were positive than those of the sigma and rectum. The concentration of cells with receptors in positive cancer cases tended to be low or medium-low.
APA, Harvard, Vancouver, ISO, and other styles
9

Nidoieva, Z. M., and A. P. Latsyshyna. "Effect of progesterone on the MGMT gene expression in MCF7, HEp-2 and 293 cells." Visnik ukrains'kogo tovaristva genetikiv i selekcioneriv 18, no. 1-2 (January 29, 2021): 16–21. http://dx.doi.org/10.7124/visnyk.utgis.18.1-2.1350.

Full text
Abstract:
Aims: to investigate the steroid hormone progesterone effect on the human MGMT gene expression at the mRNA and protein levels in cell lines with different expression patterns of the nuclear progesterone receptors and membrane receptor PGRMC1. Methods: cell culture, RNA / protein isolation, cDNA synthesis, real-time polymerase chain reaction, Western blot analysis. Results: We observe the MGMT gene upregulation by progesterone at both mRNA and protein levels. Conclusions the effect of progesterone on MGMT expression is more complex than direct regulation through the classical nuclear receptor.Keywords: O6-methylguanine-DNA methyltransferase (MGMT), progesterone, nuclear progesterone receptors (nPR), progesterone receptor membrane component 1 (PGRMC1), gene expression regulation.
APA, Harvard, Vancouver, ISO, and other styles
10

Brocklehurst, D., C. E. Wilde, J. A. Finbow, R. Brett, A. E. Champion, and D. G. Dewhurst. "Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: a short-term study." Clinical Chemistry 35, no. 2 (February 1, 1989): 238–40. http://dx.doi.org/10.1093/clinchem/35.2.238.

Full text
Abstract:
Abstract This short-term study of the relative importance of estrogen and progesterone receptors shows that progesterone receptor correlates better than estrogen receptor with tumor recurrence regardless of lymph-node status. Life-table analysis has effectively identified only two groups of patients that may be classified by progesterone receptor status alone. Progesterone-receptor negativity correlated well with tumors of histological Grade III; estrogen-receptor positivity correlated with Grade I and II tumors. The earlier recurrence of Grade III breast tumors may explain why progesterone receptor is a better prognostic indicator than estrogen receptor in short-term studies.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Receptory progesteronowe"

1

Carvalhosa, Artur Aburad de. ""Pesquisa dos receptores de estrógeno (RE) e do receptor da progesterona (RP) in vivo e verificação da influência destes hormônios in vitro em duas linhagens de adenomas pelomórficos"." Universidade de São Paulo, 2001. http://www.teses.usp.br/teses/disponiveis/23/23141/tde-02042004-115521/.

Full text
Abstract:
RESUMO A similaridade entre o tecido da mama e o da glândula salivar está bem estabelecida. A porção das estruturas acinares e ductais destes órgãos são basicamente semelhantes. Estes aspectos, associados ao fato de que uma coexistência de carcinomas da mama e de glândula salivar, têm sido relatados em uma incidência maior do que a esperada. Guiaram estudos tentando determinar a importância dos receptores de estrógeno e progesterona em adenomas pleomórficos (AP). A neoplasia é mais freqüente nas glândulas salivares e exibe uma predileção para o sexo feminino. Recentemente a presença do receptor de estrógeno (RE) e do receptor de progesterona (RP) tem sido investigada no AP, entre outras neoplasias de glândula salivar, questionando-se a possibilidade da existência da dependência hormonal. A expressão dos receptores hormonais nos carcinomas de mama é importante para determinar o prognóstico e a probabilidade de responder à manipulação hormonal. Neoplasias que apresentam positividade para ambos os receptores, estrógeno e progesterona, exibem maior probabilidade de resposta à terapia anti-estrogênica do que as neoplasias que são negativas para estes receptores. Baseando-se na literatura científica pertinente, o presente trabalho se propõe a investigar a presença da proteína RE e da proteína RP em APs humanos, relacionando-os com a proliferação de linhagens celulares sob a influência destes hormônios. A técnica utilizada foi a imuno-histoquímica para a pesquisa dos RE e RP em 10 APs emblocados em parafina pertencentes ao arquivo do Serviço de Patologia Cirúrgica da FOUSP, e de duas linhagens de APs estabelecidas no mesmo serviço: uma derivada de um paciente do sexo masculino e a outra de um paciente do sexo feminino. No meio de cultivo onde subculturas destas células proliferavam foram diluídos 17-b-estradiol e progesterona. Através de contagens destas células em períodos pré-determinados (24 horas, 48 horas e 72 horas), pretendeu-se verificar a influência dos respectivos hormônios na multiplicação celular. Como controle positivo utilizou-se uma linhagem denominada T-47D, que foi largamente estudada na literatura. A T-47D é derivada de um carcinoma metastático de mama, reconhecidamente hormônio dependente. E como controle negativo, utilizou-se de uma linhagem de carcinoma epidermóide, denominada HN30. Encontrou-se positividade para o RE em 7 de 10 APs estudados (4 em homens e 3 em mulheres) e positividade para o RP em 8 Aps estudados (4 em mulheres e 4 em homens). Pela análise estatística, constatou-se que existe uma diferença significativa no índice proliferativo entre o controle e as células submetidas à ação do 17-b-estradiol e da progesterona. Para a linhagem derivada do paciente do sexo masculino houve diferença entre o controle e as células expostas ao 17-b-estradiol e a progesterona somente nas últimas 72 horas. Para a linhagem derivada do sexo feminino constatou-se uma diferença significativa entre o controle e as células sob a influência da progesterona, a partir de 48 horas de proliferação celular. A diferença significativa entre o controle e as células sob a ação do 17-b-estradiol ocorreu somente a partir das 72 horas, sugerindo que o AP poderia ser uma neoplasia influenciada pela ação hormonal.
SUMARY It is well established the similarity between mammary and salivary glands especially between the acinic and ductile structures. These aspects, associated to the fact of coexistence of breast carcinomas and of salivary gland tumors been described, leaded studies in attempt to determine the importance of the ERs and Pr in pleomorphic adenomas (PA), the most frequent salivary gland tumor and with predilection for the females. Lately, the presence of ERs and of the PRs has been investigated in PA and other salivary gland tumors pointing out their hormonal dependency. The expression of hormone receptors in breast carcinomas is crucial to determine a presence for both receptors. These tumors exhibit better response to anti-estrogenic therapy than the negative ones. Basing on the pertinent scientific literature, the present study proposes to investigate the presence of the RE and of the RP in humans PA and connecting them with cellular proliferation in vitro, under the influence of these hormones. Immunohistochemistry technique was used for the detection of RE and RP in paraffin embedded 10 PAs from the files of the Department of Oral Pathology, School of Dentistry, University of São Paulo, and two PA cell lines one from a male patient and other female. The culture midia was supplied with, 17-b-estradiol and progesterone. A growth curve was performed (24 hours, 48 hours and 72 hours) to verify the influence of the respective hormones in the cellular proliferation. As a positive control T-47-D cells derived from a hormone dependent metastatic breast carcinoma were used, and as negative control HN30 cells, derived from a tongue squamous cell carcinoma. 7 of 10 PAs were positive (4 in men and 3 in women) for RP and 8 of 8 PAs (4 in women and 4 in men) for RE. The statistical analysis verified a significant difference in the proliferative index between the control cells and the ones submitted to the action of the 17-b-estradiol and of the progesterone: for male derived lineage a difference was only observed in the last 72 hours. In the other hand, for the female derived lineage a significant difference was verified starting from 48 hours, suggesting that PA can be influenced by hormonal action.
APA, Harvard, Vancouver, ISO, and other styles
2

Szymanski, de Toledo Maria Carolina 1982. "Expressão dos receptores de estrógeno, progesterona, andrógeno e HER2 no câncer epitelial de ovário : Expression of estrogen, progesterone, androgen and HER2 receptors in the epithelial ovarian cancer." [s.n.], 2012. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310530.

Full text
Abstract:
Orientadores: Luis Otávio Zanatta Sarian, Sophie Françoise Mauricette Derchain
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-11-07T13:36:45Z (GMT). No. of bitstreams: 1 Toledo_MariaCarolinaSzymanski_M.pdf: 838964 bytes, checksum: 3c546db1a656989db9f433b93287b2d2 (MD5) Previous issue date: 2012
Resumo: Introdução: o câncer de ovário é comumente diagnosticado em estágios avançados, sendo atualmente a neoplasia ginecológica de maior letalidade. As pesquisas têm direcionado esforços na tentativa de descobrir novos fatores prognósticos e métodos terapêuticos. Muitos trabalhos estudam a expressão dos receptores de esteróides (dentre eles, estrógeno (RE), progesterona (RP) e andrógeno (RA)) e HER2 (receptor estimulador de crescimento epitelial - subtipo 2) como fatores prognósticos e associados à resposta terapêutica, apresentando; entretanto, resultados conflitantes. Até onde conhecemos, não há estudos desta natureza no Brasil. Objetivo: Correlacionar à expressão dos RE, RP, RA e HER2 aos fatores clínico patológicos, ao intervalo livre de doença e à sobrevida nos cânceres epiteliais de ovário. Material e métodos: Este é um estudo observacional de coorte retrospectiva. Foram incluídas 152 mulheres com tumores epiteliais malignos, selecionados através dos prontuários no período de 1993 a 2008, no Centro de Atenção Integral à Saúde da Mulher (CAISM) da Universidade Estadual de Campinas - UNICAMP, São Paulo, Brasil. A avaliação da expressão dos RE [subtipos alfa (RE?) e beta (RE?)], RP, RA e HER2 foram realizadas por imunoistoquímica através da construção de microarranjos de tecidos (TMA). Inicialmente, foi realizada análise uni variada da expressão dos receptores acima quanto à idade, estado menopausal, índice de massa corpórea (IMC), tipo histológico, grau histológico, estadiamento inicial de acordo com a classificação proposta pela FIGO e presença de doença residual pós-tratamento cirúrgico. Em seguida, as pacientes foram divididas em dois grupos: ausência da expressão de RE?, RP e HER2 (triplo negativo) e positividade para pelo menos um desses receptores (não triplo negativo); e, avaliadas em relação aos critérios clínicos e epidemiológicos acima. Foram, então, realizadas análises multivariadas dos padrões de expressão de RE ? e ?, RP, RA, HER2 e triplo negativo em relação a estes mesmos critérios. Por fim, análise de sobrevida multivariada foi realizada utilizando-se todos os padrões de expressão e os fatores clínicos epidemiológicos estudados. Resultados: Nas análises multivariadas, mostraram-se significativas as seguintes associações: do receptor de estrógeno alfa (ER?) com tumores de grau histológico menos diferenciado (p=0.01); do receptor de progesterona (RP) à obesidade (p= 0.01); do receptor de andrógeno (RA) com tumores do subtipo seroso (p= 0.01); do receptor de HER2 com tumores dos graus histológicos II-III (p=0.02); do subgrupo triplo negativo com tumores de grau histológico menos diferenciado (II-III) (p<0.01). Não houve associação do RE? com nenhum dos fatores estudados. Quanto à análise multivariada de sobrevida livre de doença e sobrevida global; dentre os padrões de expressão de receptores, apenas o RE? esteve associado com melhor sobrevida livre de doença (RR=0.39; 95%CI 0.17 -0.90). Conclusões: A expressão do RE? esteve mais significativamente associada a fatores clínicos de pior prognóstico. O RP esteve associado à obesidade. O RA esteve significativamente mais presente nos tumores serosos. A expressão do HER2 e a presença de tumores triplo negativo foram maiores em tumores menos diferenciados. Paradoxalmente; o RE? foi o único receptor a apresentar associação com maior sobrevida livre de doença apesar de sua relação significativa com fatores reconhecidos de pior evolução clínica. Não houve diferença estatística significativa na análise multivariada de sobrevida total e sobrevida livre de doença quanto ao grupo de tumores triplo negativo
Abstract: Introduction: Ovarian cancer is commonly diagnosed in advanced stages and currently is the most lethal gynecological malignancy. Surveys have focused efforts in an attempt to discover new prognostic and therapeutic methods. A plenty of studies investigates the expression of steroid receptors (among them, estrogen (ER), progesterone (PR) and androgen AR)) and HER2 (epidermal growth receptor stimulator - subtype 2) as prognostic factors and associated to therapeutic response, presenting, however, conflicting results. As far as we know, there are no studies of this nature in Brazil. Objective: The aim of this study was to correlate the expression of ER (subtypes ? (ER ?) and ? (ER ?), PR, AR and HER2 to clinical pathological factors, the disease-free survival and overall survival of epithelial ovarian cancers. Methods: This is a retrospective observational cohort study. The study included 152 women with malignant epithelial tumors, selected through the records from 1993 to 2008, in the Centro de Atenção Integral à Saúde da Mulher (CAISM) at the State University of Campinas - UNICAMP, São Paulo, Brazil. The expression of ER (? and ?), PR, AR and HER2 was evaluated by immuno histochemistry through tissue microarray (TMA) technique. Initially, univariate analyses were performed, evaluating the expression of each receptor mentioned above to age, menopausal status, body mass index (BMI), histological type, histological grade, initial staging as preconized by FIGO staging of ovarian tumors and presence of residual disease after surgical treatment. Then, the patients were divided into two groups: absence of the expression of ER?, PR and HER2 (triple negative) and positive for at least one of these receptors (not triple negative), and evaluated in relation to the clinical and epidemiological criteria mentioned above. Multivariate analyzes were performed with ER ?, ER?, PR, AR, HER2 and triple negative towards these same criteria. At last, multivariate survival analyses were conducted using all the patterns of receptors' expression, epidemiological and clinical factors studied. Results: In multivariate analyzes, there were the following significant associations: of the estrogen receptor alpha (ER?) with less differentiated histological grade tumors (p = 0.01); of the progesterone receptor (PR) to obesity (p = 0.01); of the androgen receptor (AR) with the serous tumors (p = 0.01); of the HER2 receptor with tumors of histological grades II-III ( p = 0.02); of the triple negative subgroup with less differentiated histological grade tumors (II-III) (p <0.01). There was no association of the ER? with any of the factors studied. In the multivariate analysis of disease-free survival and overall survival; considering the patterns of receptors' expression, only the ER? expression was associated with better disease-free survival (RR= 0.39, 95% CI 0.17 to 0.90). Conclusions: The expression of ER? was more significantly associated with clinical factors of poor prognosis. The PR was associated with obesity. The AR was significantly more prevalent in serous tumors. The HER2 expression and the presence of triple negative epithelial ovarian cancer tumors were higher in less differentiated tumors. Paradoxically, the ER? was the only receptor which showed association with better disease-free survival despite its significant relationship with recognized factors of worse clinical outcome. There was no statistically significant difference in multivariate analysis of overall survival and disease-free survival regarding to the triple negative group
Mestrado
Oncologia Ginecológica e Mamária
Mestra em Ciências da Saúde
APA, Harvard, Vancouver, ISO, and other styles
3

Tran, Thuyet Van. "Modulation of folate receptor-[alpha] by glucocorticoid receptor and progesterone receptor." Connect to full-text via OhioLINK ETD Center, 2004. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=mco1104777244.

Full text
Abstract:
Thesis (Ph. D.)--Medical College of Ohio, 2004.
"In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Medical Sciences." Major advisor: Manohar Ratnam. Includes abstract. Document formatted into pages: iii, 293 p. Title from title page of PDF document. Includes bibliographical references (p. 175-281).
APA, Harvard, Vancouver, ISO, and other styles
4

Tran, Thuyet Van. "Modulation of Folate Receptor-alpha by Glucocorticoid Receptor and Progesterone Receptor." University of Toledo Health Science Campus / OhioLINK, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=mco1104777244.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yu, Yue. "The progesterone receptors in human prostate." Thesis, University of British Columbia, 2014. http://hdl.handle.net/2429/46509.

Full text
Abstract:
The prostate composes of epithelium and stroma, both of which are kept in balance to maintain normal prostate function. The balance between epithelium and stroma can be disrupted by the abnormal growth of stromal cells which results in prostate diseases such as benign prostatic hyperplasia. The epithelial-stromal interaction plays important roles not only in normal prostate homeostasis maintaining but also in prostate cancer development and progression. In prostate tumor, cancer associated fibroblasts enhance the secretions of cytokines and growth factors to favor cancer cells growth and metastasis. Androgen receptors are reported to regulate the development and maintenance the function of prostate. Progesterone receptor (PR) which belongs to the same steroid hormone receptor family as androgen receptors are little known in prostate. PR was reported to express in prostate, but there is no clear conclusion about the localization and function of PR in human prostate. The objective of this thesis is to investigate the expression and function of PR in human prostate. Two PR isoforms, PRA and PRB, are detected in subsets of the human prostate stromal cells by applying immunohistochemistry assays. Both PR isoforms express specifically in human prostate stromal fibroblasts and smooth muscle cells. Both PRA and PRB are demonstrated to play an inhibitory role in prostate stromal cell proliferation. PR suppresses the expression of cyclin A, cyclinB and cdc25c to delay cell cycle. PRA and PRB are demonstrated to regulate different transcriptomes by gene microarray assay. Immunohistochemistry assays were applied to human prostate cancer tissue biopsies, and PR levels are detected to decrease in the cancer associated stroma compared to the paired normal stroma. The conditioned media from PR positive stromal cell inhibit PC-3 and C4-2B cell motility through down-regulating the secretion of stromal cell derived factor 1 and interleukin 6. We conclude that PRA and PRB express in prostate stromal cells and inhibit the stromal cells proliferation. Decreased expression of PR in cancer associated stroma contributes to prostate tumor progression.
APA, Harvard, Vancouver, ISO, and other styles
6

Stavréus-Evers, Anneli. "Implantation : morphological and biochemical characterization of the receptive human endometrium /." Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-313-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hild-Petito, Sheri Ann. "Distribution of estrogen and progesterone receptors in the primate ovary, with emphasis on subpopulations of cells within the corpus luteum." Diss., The University of Arizona, 1988. http://hdl.handle.net/10150/184485.

Full text
Abstract:
Both estradiol and progeterone are proposed autocrine or paracrine regulators of ovarian function in primate species. However, specific receptors for these steroids have not been localized to individual compartments of the primate ovary. Using immunocytochemical techniques, estradiol receptors were detected in the germinal epithelium, but not other structures, of ovaries obtained from rhesus or cynomolgus monkeys during the follicular and luteal phases of the menstrual cycle. In contrast, progesterone receptors were present in stromal and interstitial tissue, the thecal layers of healthy and atretic follicles, as well as the functional corpus luteum. These results are consistent with the concept of a receptor-mediated role for progesterone, but not estrogen, within the predominant gametogenic and endocrine structures, e.g., the follicle and corpus luteum, of the primate ovary. The recent discovery of distinct cell types in the corpus luteum of domestic ungulates has revised concepts on the control of luteal function in these species. Studies were designed to test the hypothesis that the primate corpus luteum consists of cell subpopulations that differ in physical characteristics, function and regulation. Cells enzymatically-dispersed from the monkey corpus luteum at mid-luteal phase of the menstrual cycle differed in size (diameter) and the presence of the steroidogenic enzyme, 3β-hydroxysteroid dehydrogenase (3β-HSD). Analysis of dispersed cells for forward and 90° light scatter properties by flow cytometry revealed two distinct continua (Cα and Cβ). These continua were isolated using the sorting capabilities of the flow cytometer. Cα contained single cells of ≤ 15 μm and cell clusters; the cells were typically 3β-HSD-negative nonsteroidogenic. Cβ consisted of single cells that increased in size up to 40 μm and were 3β-HSD-positive. Cβ was divided into two regions (R₁ and R₃) and the cells isolated. R₁ cells were ≤ 15 μm whereas R₃ cells were ≥ 20 μm. Basal progesterone and estrogen production by R₃ cells was greater than that produced by R₁ cells (as determined by radioimmunoassay of the incubation media). Relative stimulation of progesterone production by hCG, cAMP or PGE₂ was not different between R₁ and R₃ luteal cells. These results support the hypothesis that the primate corpus luteum consists of distinct cell subpopulations which differ in size and steroidogenic capacity. However, the cell types which secrete progesterone are typically responsive to gonadotropin and PGE₂, possibly via a cAMP-mediated pathway.
APA, Harvard, Vancouver, ISO, and other styles
8

Zhu, Xiaoyan. "Progesterone in Stroke Cerebroprotection : Metabolites, Target Cells, and Role of Neural Progesterone Receptors (PR)." Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS449.

Full text
Abstract:
L’accident vasculaire cérébral (AVC) déclenche une cascade de changements qui conduisent à la mort cellulaire mais aussi des processus endogènes de protection en réponse à l'ischémie. La compréhension de ces processus est très importante pour le développement d’agents neuro-protecteurs potentiels qui peuvent être seulement des amplificateurs des processus endogènes. Le traitement par la progestérone est neuro-protecteur dans des modèles expérimentaux d’occlusion de l'artère cérébrale moyenne (MCAO). Cependant, des niveaux endogènes significatifs de progestérone sont mesurables dans le cerveau de souris mâles et femelles.Le but de notre travail était d'étudier: 1) les effets de l’ischémie sur les niveaux endogènes des stéroïdes et le rôle des récepteurs de la progestérone (PR) à la phase aiguë après ischémie chez les souris jeunes adultes et âgées des deux sexes; 2) la base cellulaire de la neuroprotection par la progestérone après ischémie et le rôle de PR neural. Nous avons utilisé un modèle d’ischémie expérimentale (MCAO); une lignée transgénique de souris (PRNesCre) dans laquelle l’expression de PR a été sélectivement invalidée dans les cellules neurales; la chromatographie en phase gazeuse-spectrométrie de masse en tandem (GC-MS/MS); et des analyses histologiques, comportementales, et d’immunofluorescence.Dans la première partie, nous avons montré que dans le cerveau de souris mâles la progestérone est principalement convertie en 5a-dihydroprogestérone (5a-DHP), qui est un agoniste naturel de PR. Après MCAO, les niveaux de progestérone et de 5a-DHP cérébrales augment chez les mâles, mais pas chez les femelles. En revanche, les femelles peuvent utiliser l’inter-conversion de la 20a-dihydroprogestérone et de la progestérone pour réguler la disponibilité des pregnanes actifs au niveau de PR. De plus, les souris PRNesCre, mâles et femelles jeunes adultes et âgées, ont des infarctus plus grands et des déficits sensori-moteurs plus importants ainsi qu’une diminution de la densité des neurones et de la microglie activée comparativement aux souris témoins PRloxP/loxP. En outre, nos résultats ont révélé des différences liées au sexe chez les souris jeunes, mais pas chez les souris âgées. Dans la deuxième partie de l'étude, nous avons montré que, chez les souris mâles PRloxP/loxP, le traitement par la progestérone améliore la récupération fonctionnelle et réduit le volume de l'infarctus. Dans le péri-infarctus, la progestérone augmente la densité des neurones, des oligodendrocytes et de leurs précurseurs, et diminue la densité des astrocytes et de la microglie activée, et l'expression de l’aquaporine 4. Ces effets de la progestérone n’ont pas été observés chez les souris PRNesCre.Nos résultats montrent 1) l'importance des pregnanes endogènes et du PR neural pour la protection cérébrale à la phase aiguë précoce après une ischémie; 2) que le traitement par la progestérone chez les souris mâles après ischémie a des effets neuro-protecteurs, pro-myélinisants et anti-inflammatoires et que PR neural est requis pour la médiation de ces effets. Ces données suggèrent fortement que les ligands de PR ou des agents ciblant leur signalisation en aval pourraient être développés pour la neuro-protection après un AVC
Ischemic stroke initiates a cascade of changes that lead to cell death and also coordinates endogenous processes that counteract the nocuous consequences of ischemia. Understanding these processes is very important for the development of potential neuroprotectants which can be just boosters of endogenous processes. Treatment with exogenous progesterone is neuroprotective after middle cerebral artery occlusion (MCAO). However, the male and female brains contain significant amounts of endogenous progesterone.The aim of our work was to study: 1) the effects of MCAO on the endogenous levels of steroids and the role of neural progesterone receptors (PR) at the acute phase after stoke in young and aging mice of both sexes; 2) the cellular basis of the neuroprotection by progesterone following stroke and the role of neural PR. We used an in vivo model of MCAO; a transgenic mice line (PRNesCre) selectively lacking the expression of PR in neural cells; gas chromatography-tandem mass spectrometry (GC-MS/MS); and histological, behavioral, and immunofluorescence analyses.In the first part of the study, we showed that in the male mouse brain, progesterone is mainly converted to 5a-dihydroprogesterone (5a-DHP), which is a natural PR agonist ligand. After MCAO, brain levels of progesterone and 5a-DHP are rapidly upregulated in males but not in females. In contrast, females may use the interconversion of 20a-dihydroprogesterone and progesterone for regulating the availability of PR-active pregnanes. Moreover, young and aging male and female PRNesCre mice exhibited increased infarcts, severe sensorimotor deficits, and decreased densities of neurons and microglia comparatively to age-matched control mice PRloxP/loxP. In addition, our results revealed sex differences in stroke outcomes in young but not in aging mice. In the second part of the study, we showed that, in male PRloxP/loxP mice, progesterone improved sensorimotor outcomes and reduced infarct volumes. In the peri-infarct, progesterone increased the densities of neurons, oligodendrocytes and their precursors, decreased the densities of activated astrocytes and microglia, and the expression of the aquaporin 4. These beneficial effects of progesterone were not observed in PRNesCre mice.Our findings 1) uncover the importance of endogenous pregnanes and neural PR for the cerebroprotection at the early acute phase after stroke; 2) show that progesterone treatment in male mice has neuro-protectant, pro-myelinating and anti-inflammatory effects after MCAO and that neural PR is required for the mediation of these effects. These data strongly suggest that ligands of PR or agents targeting their downstream signaling could be developed for neuroprotection after stroke
APA, Harvard, Vancouver, ISO, and other styles
9

Khan, Junaid Ali. "Progesterone Receptor Isoforms : functional Selectivity and Pharmacological Targeting." Phd thesis, Université Paris Sud - Paris XI, 2011. http://tel.archives-ouvertes.fr/tel-00769945.

Full text
Abstract:
Progesterone receptor (PR) is an essential pharmacological target for contraception, female reproductive disorders as well as for hormone-dependent breast and uterine cancers. Human PR is expressed as two major isoforms PRA and PRB which behave as distinct transcriptional factors. PRA vs PRB expression is often altered under pathological conditions notably breast cancer through unknown mechanisms. In this thesis we demonstrate that down-regulations of PRB and PRA proteins are negatively controlled by key phosphorylation events involving distinct MAP kinase signaling. PRA is selectively stabilized by p38 MAPK whereas p42/44 MAPK specifically controls PRB stability leading to unbalanced PRA/PRB ratios in a ligand sensitive manner. In cancer cells, elevated extracellular stimuli such as epidermal growth factors or pro-inflammatory cytokines that preferentially activate p42/44 or p38 MAPK respectively may result in opposite variations in PRA/PRB expression ratio. These results may explain altered PRA/PRB ratios often associated with breast tumors. To get a mechanistic understanding of how varied PRA/PRB ratio contributes in cell signaling, we generated an original bi-inducible PR-isoform cell model allowing selective, reversible and dose-dependent expression of PRA and/or PRB, enabling fine-tune adjustment of PRA/PRB ratio in the same cells. Using this cell-based system, we undertook genome-wide transcriptomic studies to investigate transcriptional regulation driven by unliganded and liganded PR isoforms. We report that several aspects of PR signaling such as target gene selection/transcriptional regulation, cross-talk with growth factors and antiproliferative efficacy of antiprogestin are highly dependent upon variation in PRA/PRB ratio. A new potential therapeutic strategy in PR-dependent pathological conditions may rely on the use of PR antagonists. Most of the currently available antiprogestins such as mifepristone present partial agonist activity and are not selective to PR leading to undesirable side effects. Therefore, in a collaborative project we have synthesized and characterized several new PR antagonist compounds named as APRn. Structure-activity relationship studies allowed identification of the key substitutions in steroidal skeleton responsible for agonist/antagonist character of these molecules. Several selected APRn lack partial agonist effect, are PR specific and inhibit PR transcriptional properties through a new passive mechanism of action i.e. impaired recruitment of transcriptional coregulators. Such PR selective antagonists devoid of partial agonist character might provide important therapeutic perspectives for various reproductive tract abnormalities and hormone-dependent uterine and breast cancers. Altogehter, our results provide mechanistic insights into the functional selectivity of PR isoforms and their pharmacological targeting by the use of PR antagonists.
APA, Harvard, Vancouver, ISO, and other styles
10

Bolden-Tiller, Olga U. "Characterization of progesterone receptor in bovine corpora lutea /." free to MU campus, to others for purchase, 2002. http://wwwlib.umi.com/cr/mo/fullcit?p3074376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Receptory progesteronowe"

1

Pertschuk, Louis P. Immunocytochemistry for steroid receptors. Boca Raton: CRC Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gillan, David. Immunocytochemical demonstration of progesterone receptors in breast cancer cells: Relationship with degree in tumor differentiation. [S.l: The Author], 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1941-, Ganten D., Pfaff Donald W. 1939-, and Kato Junzo, eds. Actions of progesterone on the brain. Berlin: Springer-Verlag, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Oregon Regional Primate Research Center., ed. Distribution of estrogen and progesterone receptors in the primate ovary: With emphasis on subpopulations of cells within the corpus luteum. 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Prater, Patrice L. Physiological factors affecting ovine uterine estrogen and progesterone receptor concentrations. 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yu, Celeste. The role of progesterone receptor co-repressors in the functional withdrawal of progesterone at term pregnancy. 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

M, Berstein Lev, and Santen Richard J, eds. Innovative endocrinology of cancer. New York: Springer Science+Business Media, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Santen, Richard J., Lev M. Berstein, and various. Innovative Endocrinology of Cancer. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Henry, Linda. Production, characterisation and clinical application of monoclonal antibodies to the human oestrogen and progesterone receptors. 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Aerts, Joeri. Progesterone Induces Apoptosis in Eosinophilic Granulocytes & Induces Tumour Necrosis Factor-Alpha / Tumour Necrosis Factor Receptor. Leuven Univ Pr, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Receptory progesteronowe"

1

Müller, Judith M., and Roland Schüle. "Sex Steroid Receptors: Androgen Receptor, Estrogen Receptors, Progesterone Receptor." In Encyclopedia of Molecular Pharmacology, 1–7. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-21573-6_163-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Müller, Judith M., and Roland Schüle. "Sex Steroid Receptors: Androgen Receptor, Estrogen Receptors, Progesterone Receptor." In Encyclopedia of Molecular Pharmacology, 1415–21. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-57401-7_163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Renoir, J. M., and E. E. Baulieu. "Progesterone Receptor Purification." In Receptor Purification, 219–39. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-0477-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ward, Tony Milford. "Progesterone Receptor." In Proteins and Tumour Markers May 1995, 1331. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0681-8_68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lange, Carol A., Carol A. Sartorius, Hany Abdel-Hafiz, Monique A. Spillman, Kathryn B. Horwitz, and Britta M. Jacobsen. "Progesterone Receptor Action:." In Advances in Experimental Medicine and Biology, 94–111. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-78818-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Smith, David F., and David O. Toft. "Purification of Nontransformed Avian Progesterone Receptor." In Receptor Purification, 241–57. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-0477-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Weigel, Nancy L. "Purification and Characterization of Chicken Progesterone Receptor." In Receptor Purification, 259–83. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-0477-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Conneely, Orla M. "Progesterone Receptors and Ovulation." In Handbook of Experimental Pharmacology, 37–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-02062-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Martin, Mary Beth, Miguel Saceda, and Ralph K. Lindsey. "Estrogen and progesterone receptors." In Regulatory Mechanisms in Breast Cancer, 273–88. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3940-7_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Robker, Rebecca L., and JoAnne S. Richards. "Progesterone: Lessons from the Progesterone Receptor Knockout." In Ovulation, 121–29. New York, NY: Springer New York, 2000. http://dx.doi.org/10.1007/978-0-387-21508-2_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Receptory progesteronowe"

1

Basu, Gargi D., Ariane Kemkes, Rebecca A. Feldman, David R. Arguello, Alan Wright, David Loesch, and Raheela Ashfaq. "Abstract 3152: Distribution of hormone receptors (estrogen receptor, progesterone receptor and androgen receptor) in epithelial malignancies." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3152.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Révillion, F., C. Lindet, V. Lhotellier, L. Hornez, J. Bonneterre, J. Bonneterre, and J. Peyrat. "Relationships between Progesterone Receptor Isoforms and the HER Receptors and Ligands Network in 299 Primary Breast Cancers." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-4150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Young, Amy, Jane Guan, Anneleen Daemen, Lori Friedman, and Kui Lin. "Abstract B36: Progesterone receptor signaling in estrogen receptor-positive breast cancer." In Abstracts: AACR Special Conference: Advances in Breast Cancer Research; October 7-10, 2017; Hollywood, CA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1557-3125.advbc17-b36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mehta, Fabiola, Young A. Yoo, Jieun Son, Francesco J. DeMayo, John P. Lydon, and Sang-Hyuk Chung. "Abstract A19: Progesterone receptor signaling inhibits cervical cancer." In Abstracts: AACR Special Conference: The Translational Impact of Model Organisms in Cancer; November 5-8, 2013; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1557-3125.modorg-a19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Geronymo, Beatriz Baaklini, Filomena Marino Carvalho, Adriana Akemi Yoshimura, Juliana Zabukas de Andrade, Danúbia Ariana de Andrade, and Alfredo Carlos Simões Dornellas de Barros. "CORRELATION BETWEEN THE PRESENCE OF ANDROGENIC RECEPTORS AND MOLECULAR AND HISTOPATHOLOGICAL VARIABLES IN BREAST CANCER." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1061.

Full text
Abstract:
Introduction: The expression of androgenic receptors (AR) is a new predictive marker of response and prognosis in invasive breast carcinoma (BC). It emerges as a potential therapeutic target. Objectives: To evaluate the frequency of AR positivity and its correlation with molecular and histopathological parameters in infiltrative BC. Methods: Retrospective cohort study, analyzing 119 cases of non-metastatic invasive BC, seen at a private clinic. Hormonal receptors were screened by immunohistochemical reaction, and AR were considered positive when present in at least 10% of cells, ER and PR from 1%. This finding was correlated with pathological staging, histological grade (HG), vascular-lymphatic invasion (VLI), estrogen receptors (ER), progesterone receptors (PR), HER2 and Ki 67. Results: AR were positive in 96 cases (80.6%). The correlation with the surveyed parameters can be seen in the table. Conclusions: AR positivity is associated with more differentiated hormone-dependent tumors and with a lower proliferation rate.
APA, Harvard, Vancouver, ISO, and other styles
6

Rogalsky, Johanna Elisabeth, Sergio Ossamu Ioshii, and Lucas Ferrari de Oliveira. "Automatic ER and PR scoring in Immunohistochemistry H-DAB Breast Cancer images." In Simpósio Brasileiro de Computação Aplicada à Saúde. Sociedade Brasileira de Computação - SBC, 2021. http://dx.doi.org/10.5753/sbcas.2021.16075.

Full text
Abstract:
Breast Cancer (BC) is the most frequently diagnosed cancer for women. This way, the Brazilian Unified Health System (SUS) focuses on studying the disease and improving all the steps involved in dealing with BC. The presence or absence of the Estrogen Receptor (ER) and the Progesterone Receptor (PR), which define invasive subtypes, is detected through Immunohistochemistry (IHC). One way to assist the manual assessment of pathologists and histopathologists is to develop automatic scoring systems. Fortunately, digital pathology is increasingly achieving higher agreement with the pathologist. Therefore we create an automatic scoring system composed of image preprocessing, feature extracting, and classification achieves a 69% f-score rate.
APA, Harvard, Vancouver, ISO, and other styles
7

Souza, Priscila M., Filomena M. Carvalho, Fernando N. Aguiar, Débora Gagliato, and Alfredo C. S. D. Barros. "ASSOCIATION BETWEEN GATA3 AND PATHOLOGIAL AND IMMUNOHISTOCHEMICAL PREDICTIVE AND PROGNOSTIC PARAMETERS IN EARLY BREAST CANCER." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1046.

Full text
Abstract:
Introduction: GATA3 gene, at 10p14, a member of the GATA family with two GATA-type zinc-fingers, encodes the transcription factors GATA - binding protein 3 (GATA3), critical for the luminal breast epithelium development and maintenance. The GATA3 protein is a linear one, with more than 400 aminoacids, that can be recognized by immunohistochemical analysis. Mutations of the GATA3 and loss of the expression of its related protein are implicated in breast cancer development and aggressiveness. As the most frequent transcription factor in luminal tumor cells, GATA3 became an important marker of mammary differentiation in neoplasias of unknown origin, better than mammaglobin and gross cystic disease fluid protein (GCDFP). Objectives: In this study, we aimed at assessing pathological and immunohistochemical variables and their association with GATA3 expression, adding bases for breast carcinogenesis comprehension and BC (Breast Cancer) precision therapy. Methods: GATA3 was analyzed by immunohistochemistry in whole histological sections of tumors from 105 female patients with histological diagnosis of invasive breast carcinoma and at clinical stages I, II and IIIA, who underwent primary surgical treatment (protocol approval number: 1,604,792). GATA3 nuclear expression was determined in percentage of tumor cells and categorized as preserved (positive expression in more than 95% of cells) or reduced (negative or expression in up to 95% of tumor cells). GATA3 expression was analyzed according to patient’s age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, estrogen receptor, progesterone receptor, androgen receptor, HER2 status, and Ki-67. Results: GATA3 expression was detected in 103/105 (98.1%) cases. Reduced expression was associated with higher histological and nuclear grade, negative hormonal receptors, HER2-positive and higher proliferative activity according to Ki-67 expression. Triple negative breast carcinomas (TNBC) and ER-negative/HER2-positive presented the highest frequency of GATA3 reduction (75%) compared to ER-positive/HER2-negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in TNBC tended to be higher among tumors with GATA3 reduced, irrespective of androgen receptor expression. In the group of ER-positive/ HER2-negative tumors only 3 cases presented GATA3 reduction, all of them with high proliferative activity. Conclusions: GATA3 expression is present in almost all cases of early breast cancer. Reduction in its expression is associated with adverse prognostic factors and higher proliferative activity in all subtypes, including ER-positive/HER2-negative tumors.
APA, Harvard, Vancouver, ISO, and other styles
8

Mansani, Fabio Postiglione, Mariane Marcelino Fernandes, Mario Rodrigues Montemor Netto, and Cristiane da Costa Bandeira Abrahão Nimir. "COMPARATIVE ANALYSIS BETWEEN IMMUNOHISTOCHEMISTRY PATHOLOGICAL SUBTYPING AND MAMMAPRINT® GENETIC SIGNATURE IN PATIENTS WITH BREAST CANCER IN BRAZIL: A PILOT STUDY." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2098.

Full text
Abstract:
Introduction: Immunohistochemistry, in breast cancer samples, measures the expression of biomarkers such as estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67. Using the positivity or negativity of the receptors and the Ki67 value, this method, along with the histological results, allows the doctors to classify the tumors into four types as follows: Luminal A, Luminal B, HER2, and basal/triple negative. Genetic signature is a tool involving in numerous studies in this area; however owing to the difficulty of access to the tests, its usefulness is still limited. MammaPrint® was the first test approved by the Food and Drugs Administration (FDA) in 2007 to measure prognostic value associated with breast cancer recurrence and classify patients with breast cancer into “low risk” or “high risk” of developing metastases within the first 10 years after diagnosis and elucidates the patient’s need for adjuvant chemotherapy. It categorizes tumors into subtypes based on biological homogeneity. This study aims to analyze the concordance between the results of immunohistochemistry pathological subtyping and MammaPrint®, which is accompanied by BluePrint®, for the classification and stratification of luminal breast cancer. Material and Methods: Data were collected from the medical records of 19 patients in the Instituto Sul Paranaense de Oncologia (ISPON) who presented immunohistochemistry and genetic test compatible with luminal tumors. Immunohistochemistry was evaluated through hormone receptors, HER2 and mainly Ki67, as defined by the 2013 St. Gallen guidelines (50% of the sample were centrally assessed). For classification by the genetic test, BluePrint® provided the molecular subtype data and MammaPrint® stratified the risk, establishing Luminal A tumors as low risk and Luminal B as high risk. The concordance between the immunohistochemical classification and the genetic test was evaluated with the nonparametric McNemar-Bowker test. The Ki67 cutoff value predictive for recurrence risk compared with MammaPrint® was accessed by the ROC curve. Results: The results showed that, on one side, only 33.3% of patients classified as Luminal A by immunohistochemistry were also classified by the genetic signature as Luminal A. On the other side, on the tumors classified as Luminal B, 60% presented agreement between the classifications. Overall agreement among the tests was 47.3%. The cutoff value found for Ki67 predictive of tumor recurrence risk was ≤5, with a sensitivity of 100% and a specificity of 33%. The agreement between hormonal receptors and HER2 with BluePrint® was 100%. Conclusion: This study provides preliminary data regarding the prognostic and predictive value of genetic and molecular tests — represented by MammaPrint®/BluePrint® and immunohistochemistry—in a sample of Brazilian population, evidencing a discrepancy between the methods. The cutoff value of Ki67 predictive for recurrence risk remains under discussion, since there is no standardization of its measurement methodology. As a result, new studies could be developed, with larger and multicentric samples.
APA, Harvard, Vancouver, ISO, and other styles
9

Lima, Beatriz Alves, Andressa da Silva Pereira, Bruna Alves Lima, Diana Gonçalves Lima, Leonardo Ferreira Pucci, Renato Moraes Ferreira, Tiago Castro Ferreira, and Henrique Ferreira Pucci. "PREDICTORS OF BREAST CANCER PROGNOSIS BASED ON TUMOR BIOMARKERS." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2022.

Full text
Abstract:
Objective: To analyze the tumor biological markers of breast cancer associated with the prognostic of the disease. Methodology: A systematic review was carried out on the Scielo, PubMed, and the National Cancer Institute databases on the topic. Descriptors used were: tumor biomarkers, breast cancer, and prognosis. Thus, 15 articles published between 2001 and 2020 were selected. Results: Breast cancer, characterized by the disordered multiplication of breast cells, is the most incident in women in the world, representing 24.2% of the total cases in 2018, and the most frequent cause of death in this gender. Accordingly, tumor markers are complementary tests for early diagnosis, since they are macromolecules derived from the tumor and biological fluids. The evaluation of tumor markers is of paramount importance due to the great diversity in clinical progression of breast cancer, for example, those hormone receptors (estrogen and progesterone), MIB-1, Ki-67, PCNA, p53, and c-erbB-2. Hence, about two-thirds of breast cancers are positive for hormone receptors and are related to a more favorable prognosis. PCNA (36 kDa protein perceptible in the cell nucleus from the late G1 to the S phase of the cell cycle) and MIB-1 (direct antibody against parts of the Ki-67 antigen) have a high proportion of tumor cells associated with a high-degree tumor differentiation, indicating a worse prognosis. Furthermore, mutations in the p53 and c-erbB-2 genes report low levels of estrogen and progesterone receptors, leading to a worse prognosis. Conclusion: In brief, the recognition of the main markers helps in the identification of patients with potentially aggressive tumors and in the mortality reduction of breast cancer, through treatments that can alter the course of the disease. On account of this, it is known that the tumor markers must be used in combination with the other methods such as diagnostic, prognostic, and therapeutic modifications.
APA, Harvard, Vancouver, ISO, and other styles
10

Gibson, Katelin A., Merit L. Goodman, and Christy R. Hagan. "Abstract 5228: Mammary gland tumors in progesterone receptor transgenic mice." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5228.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Receptory progesteronowe"

1

Hagan, Christy R. Progesterone Receptor Scaffolding Function in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2012. http://dx.doi.org/10.21236/ada568199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hagan, Christy. Progesterone Receptor Scaffolding Function in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2011. http://dx.doi.org/10.21236/ada601953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Horwitz, Kathryn B. Hormone Resistance and Progesterone Receptors in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada375134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Conneely, Orla M. The Physiological Role of Progesterone Receptors in Breast Development and Tumorigenesis. Fort Belvoir, VA: Defense Technical Information Center, September 1997. http://dx.doi.org/10.21236/ada341326.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mullany, Lisa K., and Carol A. Lange. Cell Cycle Dependent Regulation of Human Progesterone Receptor in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2004. http://dx.doi.org/10.21236/ada433995.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sartorius, Carol A. Progesterone Receptor Isoform Influence on Human Breast Tumor Growth and Hormone Treatment. Fort Belvoir, VA: Defense Technical Information Center, January 2003. http://dx.doi.org/10.21236/ada413325.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Richer, Jennifer K., and Nicole G. Manning. Role of Progesterone Receptor Isoforms in Regulation of Cell Adhesion and Apoptosis. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada407539.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Yixian. Regulation of Agonist--and Antagonist--Mediated Activation of Human Progesterone Receptors by Phosphorylation. Fort Belvoir, VA: Defense Technical Information Center, July 1996. http://dx.doi.org/10.21236/ada315692.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhang, Yixian. Regulation of Agonist- and Antagonist-Mediated Activation of Human Progesterone Receptors by Phosphorylation. Fort Belvoir, VA: Defense Technical Information Center, July 1995. http://dx.doi.org/10.21236/ada303820.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Keightley, Maria C. The Mechanism by Which Agonist and Antagonist Occupied Progesterone Receptors Regulate Target Genes. Fort Belvoir, VA: Defense Technical Information Center, June 1998. http://dx.doi.org/10.21236/ada350945.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Receptory progesteronowe' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography